MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price traded up 0.7% on Friday . The stock traded as high as GBX 1.54 and last traded at GBX 1.51. 430,716 shares traded hands during trading, an increase of 924% from the average session volume of 42,065 shares. The stock had previously closed at GBX 1.50.
MaxCyte Trading Up 0.7%
The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81. The firm has a fifty day moving average price of GBX 1.57 and a 200 day moving average price of GBX 5.80. The company has a market cap of £1.61 million, a price-to-earnings ratio of -0.04 and a beta of 1.13.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Featured Articles
- Five stocks we like better than MaxCyte
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- Best $19 you’ll spend this year.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
